<DOC>
	<DOC>NCT01454011</DOC>
	<brief_summary>The study is designed to answer the following questions: 1. Is there any difference between the compositions of the HDL cholesterol subpopulations of patients with hypogonadism and the healthy controls. 2. What is the effect of testosterone replacement therapy on the distributions of HDL subgroups. 3. Is there any difference between the effects of the two different testosteron replacement regiments</brief_summary>
	<brief_title>The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups</brief_title>
	<detailed_description>This study has two designs: 1. The case control design to search for the difference between the HDL subgroups and the other metabolic parameters between the healthy subjects and the patients with hypogonadism 2. The follow-up study to search for the effects of two different testosterone replacement regiments.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Congenital hypogonadotrophic hypogonadism, Male sex Previous history of androgen replacement, any chronic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone</keyword>
	<keyword>HDL cholesterol subgroups</keyword>
	<keyword>hsCRP</keyword>
	<keyword>HOMA-IR</keyword>
</DOC>